NMDA neurotransmission plays an important role in learning and memory. NMDA receptors (NMDAR) were found to decrease in the frontal lobe and hippocampus of Alzheimer's disease (AD). This study is a randomized, double-blind, placebo controlled drug trial for testing the efficacy of NMDAR-enhancer. All subjects will be allocated randomly to 4 groups: (1) DAOI-A group; (2) DAOI-B group; (3) DAOI-C group; (4) placebo group. The study period is 24 weeks. The investigators hypothesize that DAOI may yield better efficacy than placebo for cognitive function in patients with AD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
154
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24
Cognitive assessment
Time frame: week 0, 8, 16, 24
Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input at week 8, 16 and 24
Global assessment
Time frame: week 8, 16, 24
Change from baseline in speed of processing (Category Fluency) at week 24
Cognitive assessment
Time frame: week 0, 24
Change from baseline in working memory (Wechsler Memory Scale, Spatial Span) at week 24
Cognitive assessment
Time frame: week 0, 24
Change from baseline in verbal learning and memory tests (Wechsler Memory Scale, Word Listing) at week 24
Cognitive assessment
Time frame: week 0, 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Placebo